Media
Official Press Releases and Media Coverage
Our work is regularly covered by the leading media organisations around the world. This section serves as a repository of all official press releases issued by our Corporate Communications and Investor Relations teams. You can also browse through the selection of media articles on Laurus Labs and relevant reportage.
25 Apr 2024 Press Release - Financial results for the quarter and year ended March 31, 2024
25 Jan 2024 Press Release - JV Agreement with KRKA
24 Jan 2024 Press Release - Laurus Labs Financial Results Q3 FY 2024
20 Oct 2023 Press Release - Financial Results Q2 FY 2024
27 Jul 2023 Press Release - Financial Results Q1 FY 2024
22 Jun 2023 Press Release - Newspaper Advertisement
19 Jun 2023 Press Release - Laurus Labs signs Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets
31 May 2023 Press Release - Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction
02 May 2023 Press Release - Laurus Labs receives USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment
27 Apr 2023 Laurus Labs Financial Results Q4 FY 2023 Press Release
30 Jan 2023 Laurus Labs Financial Results Q3 FY 2023 Press Release
21 Oct 2022 Laurus Labs Financial Results Q2 FY 2023 Press Release
27 Jul 2022 Laurus Labs Financial Results Q1 FY 2023 Press Release
28 Apr 2022 Press Release - Q4 Press Release FY 2022
27 Nov 2021 Press Release - Laurus Labs Financial Results Q3 FY 2022
21 Nov 2021 Press Release - Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication
19 Nov 2021 Press Release titled - Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT
28 Oct 2021 Healthy Growth momentum with 17% revenue growth for H1FY22
14 Sep 2021 Press Release - Laurus Labs, Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children
29 Jul 2021 Press Release - Laurus Labs Financial Results Q1 FY 2022
02 Jul 2021 Press Release- Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO
29 Apr 2021 Laurus Labs Financial Results Q4 FY 2021 Press Release
04 Mar 2021 Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company
28 Jan 2021 Revenue growth of 76% and PAT growth of 274% in Q3 FY21
25 Nov 2020 Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences
29 Oct 2020 Laurus Labs Press Release Board Meeting Oct 29 2020
29 Oct 2020 Q2 H1 FY21 Press Release Oct 29 2020
30 Jul 2020 Press Release - Strong Revenue growth of 77% and PAT growth of 1047%
19 May 2020 Press Release - Laurus Labs receives USFDA approvals for ANDAs TLE 400 and TLE 600 tablets.
30 Apr 2020 Press Release - Highest Ever Profit after Tax at INR 2,553 mn in FY20, growth of 172%
27 Mar 2020 Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers
26 Mar 2020 Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States
30 Jan 2020 Press Release - PROFIT AFTER TAX AT INR 73.5 crs in Q3 FY20 with a growth of 313 %
21 Nov 2019 Laurus Labs completes US FDA, pre-approval inspection (P AI), for an API manufactured at its units 1&3, Visakhapatnam
08 Nov 2019 Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam
30 Oct 2019 Laurus Labs Financial Results Q2 FY 2020 Press Release
18 Sep 2019 Laurus Labs to acquire the Subsidiary Company of Aspen Pharmacare, South Africa
05 Sep 2019 Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE400 from Global Fund
02 Aug 2019 Q1 FY20 Results: Revenues up by 2 percent
22 July 2019 Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market
12 July 2019 Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam
14 June 2019 USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam
02 May 2019 FY 19 : Laurus Labs revenues up by 11.5 percent in Q4
26 Mar 2019 FY 19 : Laurus Labs enters into strategic partnership agreement with the Global Fund
11 Mar 2019 FY 19 : Laurus Labs receives two approvals from USFDA
03 Feb 2019 FY 19 : Laurus Labs received tentative approval from USFDA under PEPFAR for TLD FDC
03 Feb 2019 FY 19 : USFDA Approval for TLD Tablets and EIR from USFDA
31 Jan 2019 FY 19 : Laurus Labs Revenue Grew 11% in Q3 FY19
1 Dec 2018 FY 18 : Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa
1 Nov 2018 FY 18 : Laurus Labs Financial Results Q2 FY2019 Press Release
23 Oct 2018 FY 18 : Press Release Laurus Labs Oct 23 2018
29 Aug 2018 FY 18 : Press Release 29 Aug 2018 - Metformin USFDA Approval
03 Aug 2018 FY 18 : Press Release of Q1 Results 2018-19
10 May 2018 FY 17 : Press Release of Q4 Results 2017-18
1 March 2018 FY 17 : Intimation of completion of USFDA inspection of unit2 with no observations
29 January 2018 FY 17 : Press Release of Q3 9M Results 2017-18
17 January 2018 FY 17 : LAURUS LABS CERTIFIED AS THE “GREAT PLACE TO WORK” IN THE LARGE SIZED ORGANISATIONCATEGORY IN INDIA
9 November 2017 FY 17 : Q2 H1 Results 2017-18 Press Release
10 November 2017 FY 17 : Analyst and Investor Meet Intimation 10-11-2017
15 September 2017 FY 17 : Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection;
18 August 2017 FY 17 : Laurus Labs completed the USFDA inspection of its API facilities Unit 1 & 3 at Visakhapatnam
10 August 2017 FY 17 : Press Release of Q1 Results 2017-18
5 July 2017 FY 17 : Laurus Labs Credit Rating Improved
18 May 2017 FY 17 : Laurus Labs PAT grows by 40%
9 February 2017 FY 17 : Laurus Labs demonstrates strong Q3 growth In the first quarterly results after successful IPO
23 Jun 2021 Dr. Satyanarayana Chava's interview on Bloomberg Asia
29 Jan 2021 ET Now News
03 Aug 2020 Laurus Labs in focus, zooms over 15%; stock hits all-time high
03 Aug 2020 Story on Laurus Labs in Financial Express.
03 Aug 2020 Q1 net more than annual profit! This API maker is creating a splash on Dalal Street
31 Jul 2020 Blockbuster Q1 For Laurus Labs | Satyanarayana Chava of Laurus Labs To ET NOW
31 Jul 2020 What led to a blockbuster quarter for Laurus Labs
31 July 2020 Trending stocks: Laurus Labs shares surge over 15%
31 Jul 2020 అత్యంత ఆకర్షణీయంగా లారస్ ల్యాబ్స్ ఫలితాలు
30 Jul 2020 Laurus Labs net up 11 times to Rs 172 Cr in Q1
30 Jul 2020 Laurus Labs standalone net profit rises 832.35% in the June 2020 quarter
30 Jul 2020 Laurus Labs Q1 profit at Rs 172 crore
30 Jul 2020 Gainers & Losers: 10 stocks that moved the most on July 30
30 Jul 2020 Laurus Labs' net up 11 times to Rs 172 crore in Q1
30 Jul 2020 Laurus Labs consolidated net profit rises 1037.62% in the June 2020 quarter
26 Feb 2020 Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts
31 Jan 2020 Laurus Labs Standalone December 2019 Net Sales at Rs 720.99 crore, up 40.61% Y-o-Y
30 Jan 2020 Laurus Labs Q3 net profit rises 4-fold at Rs 73 crore
30 Jan 2020 Laurus Labs net trebles at Rs. 73.5 crore
28 Dec 2019 Laurus Labs eyes bigger play in generic formulations segment
11 Nov 2019 Laurus Labs shares up on USFDA observations on Visakhapatnam unit
01 Nov 2019 Laurus Labs consolidated net profit rises 248.86% in the September 2019 quarter
01 Nov 2019 Laurus Labs Standalone September 2019 Net Sales at Rs 705.86 crore, up 22.84% Y-o-Y
31 Oct 2019 Laurus Labs Ltd crosses revenue of Rs. 700 crores in Q2 FY20
23 Oct 2019 CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
18 Sep 2019 Laurus Labs to acquire South Africa's Aspen Pharmacare subsidiary
18 Sep 2019 Warburg Pincus-backed Laurus Labs buys South African firm
05 Sep 2019 Laurus Labs gets approval from the FDA
29 Aug 2019 Laurus Labs gets USFDA approval for Metformin tablets
05 Aug 2019 Laurus Labs Ltd CEO Satyanarayana Chava speaks on Q1 results
22 Jul 2019 Laurus Labs partner Rising Pharma launches neuropathic pain capsules in US
12 Jul 2020 Laurus Labs gets USFDA nod for Unit-4
12 Jul 2020 Laurus Labs Vizag unit completes USFDA inspection
15 Jun 2020 Laurus Labs gets 2 USFDA observations for its API facilities in Visakhapatnam
27 March 2019 Laurus Labs joins hand with Global Fund to supply drugs
26 March 2019 Laurus Labs seals deal with Global Fund to supply ARV combination medicine
26 March 2019 Laurus Labs jumps 4% on strategic partnership with Global Fund
26 March 2019 Larus Labs enters agreement with Global Fund for supply of AIDS drugs
26 March 2019 Laurus Labs firms up after partnership with Global Fund
26 March 2019 Laurus Labs in pact with The Global Fund
26 March 2019 Laurus Labs enters into strategic partnership agreement with Global Fund
14 February 2019 Laurus Labs invests over $100 million on formulation biz
03 February 2019 Laurus Labs gets USFDA approval for HIV drug
03 February 2019 Laurus Labs gets USFDA nod for HIV drug
2 December 2018 Laurus Labs-Aspen Pharmacare launch HIV drug in South Africa
3 November 2018 Laurus Labs Vizag API unit gets 1 USFDA observation
02 November 2018 Laurus Labs Vizag API unit gets 1 USFDA observation
23 October 2018 Laurus Labs to expand its footprint in US, China
30 August 2018 Laurus Labs gets USFDA nod for diabetes drug
30 August 2018 Laurus Labs rises nearly 6% post USFDA approval for diabetes drug
29 August 2018 Laurus Labs gets USFDA nod for diabetes drug
29 August 2018 Laurus Labs gets USFDA nod for diabetes drug
11 August 2017 Expect to get 2 ANDA approvals in FY18: Laurus Labs
11 August 2017 LAURAS LABS Q1: PROFIT JUMPS 51%
22 May 2017 Laurus Labs Q4 net rises 39%
19 May 2017 Laurus Labs says API facility of Unit 2 completed successful USFDA inspection
19 May 2017 Laurus Labs Vizag unit clears USFDA inspection ahead of debut in US generics market
Laurus Labs standalone net profit rises 39.11% in the March 2017 quarter
31 March 2017 Laurus Labs' PAT increases by 39% to Rs 74.3-cr.
18 May 2017 Laurus Labs posts Rs 74 crore net profit in Q4
27 March 2017 Citi bullish on Laurus; return ratios will improve post formulations: Satyanarayana Chava, Founder & CEO
Laurus Labs December quarter net up 17.5% to Rs 47 crore
10 February 2017 Laurus Labs hopes better profits in Q4 with lower interest outgo after debt retirement
10 February 2017 Laurus Labs December quarter net up 17.5% to Rs 47 crore
10 February 2017 Laurus Labs Q3 net up 18%
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
9 February 2017 Laurus Labs net profit up 17.5% to Rs 47.2 crore in Q3
9 February 2017 Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
10 February 2017 Laurus Labs December quarter net up 17.5% to Rs 47 crore
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
11 February 2017 Laurus Labs December quarter net up 17.5% to Rs 47 crore
13 February 2017 Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
9 February 2017 Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO
Laurus Labs Demonstrates Strong Q3 Growth In The First Quarterly Results After Successful IPO
